CVS · CVS Health

The thesis

CVS Health is modestly more likely to beat the S&P 500 over the next three months than to lag it. Aetna's medical costs are improving, the company raised its 2026 guidance, and the selloff after the 4 November 2026 split announcement left the shares below the level those results support. The fourth-quarter report, expected in early February 2027, settles it. That report shows whether the 2027 outlook of at least $8.65 in adjusted earnings per share holds.

The third quarter was strong. The company's 8-K results exhibit dated 4 November 2026 shows adjusted EPS of $2.09, against $1.60 a year earlier and an LSEG analyst average of $1.65, as reported by Reuters. The medical benefit ratio improved to 91.3% from 92.8%. The 2026 adjusted EPS guide rose to at least $8.20, from $7.90–8.10. On the same day, the company announced a tax-free separation into two public companies, due in the first half of 2028. The shares fell about 13% that session, according to Reuters.

The market is pricing a pause in 2027 earnings plus separation costs. The shares closed at $89.79 on 12 November 2026. That is 18.9% below the 52-week intraday high of $110.68 set on 22 July 2026, even after the guidance raise. The rating is Medium. Results and insider buying support the shares, but the separation adds costs and cash-flow questions that will not be settled before 2028.

Bullish and bearish views on CVS Health Corporation

The bull case on CVS Health Corporation (CVS), in brief: health insurance margins are recovering. The bear case: 2027 is a trough year for earnings.

Bull case

• Health insurance margins are recovering. Health Care Benefits adjusted operating income rose to $912 million in the third quarter of 2026, from $314 million a year earlier, according to the 4 November 2026 results exhibit. Total revenue was $108.4 billion, up 5.4%.
• Cash guidance rose sharply. The 2026 operating cash flow guide rose to at least $15.5 billion, from at least $11.5 billion (results exhibit, 4 November 2026). On the earnings call that day, management said share repurchases resume in the fourth quarter because the company reached its leverage target ahead of schedule.
• Management sized split costs below outside estimates. At the Wolfe Research conference on 9 November 2026, Chief Executive David Joyner said recurring costs of running two companies are closer to $500 million than the more than $1 billion some investors had estimated. One-time costs come on top. He put deployable capital across the two businesses at about $35 billion, per MarketBeat.
• The future pharmacy chief bought shares. Prem S. Shah will lead CVS Pharmacy after the split. He bought 23,855 shares on the open market at $83.89 on 6 November 2026, according to his SEC Form 4.
• The retail pharmacy outlook improved. Management said at the 9 November 2026 conference that the pharmacy business is now expected to grow at a low single-digit rate. It had earlier planned for a 5% decline. Management expects 2027 to be the third straight year of higher adjusted operating income in that business.

Bear case

• 2027 is a trough year for earnings. Management called 2027 a trough year for the continuing CVS Health because of rebate guarantees and the 340B drug pricing program, per MarketBeat on 9 November 2026. On 4 November 2026, Kevin Gade of Bahl & Gaynor called the 2027 outlook "an earnings hiccup" next to peers whose growth is speeding up, per Reuters.
• Membership and selling conditions are softening. On 4 November 2026, Chief Financial Officer Brian Newman flagged softer selling conditions and declining health plan membership for 2027, according to Reuters.
• Analysts cut targets after the report. Every target cut still sits above the 12 November 2026 close. Goldman Sachs cut its target to $115 from $120 on 6 November 2026. UBS cut to $107, also on 6 November 2026. Leerink Partners cut to $104 on 5 November 2026, Argus to $105 from $114 on 10 November 2026, and Wells Fargo to $112 on 12 November 2026.
• Credit and regulatory overhangs. On 6 November 2026, AM Best placed the ratings of Aetna Life Insurance Company and related units under review with developing implications. On 4 November 2026, UBS analyst Kevin Caliendo called the split "a defensive move against regulation," per Reuters.
• Little financial detail on the split yet. Barclays analyst Andrew Mok named the lack of financial detail on the breakup as investors' main concern on 4 November 2026, per Reuters.

Price setup

The shares closed at $81.33 on 5 November 2026, the session after the split announcement. They recovered to $89.79 by 12 November 2026. That close sits above the 50-day moving average of $89.38 and the 200-day moving average of $88.01, both as of 12 November 2026 from adjusted daily closes. The 3-month price change is −6.9%, measured from the 14 August 2026 close.

The levels that matter are on both sides. Below is the 5 November 2026 close of $81.33, the low point after the announcement. Above is the 52-week intraday high of $110.68 from 22 July 2026. The 52-week closing low was $70.08 on 27 March 2026. A close back under both moving averages would show that the post-announcement recovery is fading.

Catalysts ahead

• ~10 February 2027 (est.): Fourth-quarter 2026 results and 2027 guidance update. This report shows whether the 2027 adjusted EPS outlook of at least $8.65 per share holds and whether the medical cost improvement continued into the fourth quarter.
• ~February 2027 (est.): Medicare Advantage enrollment update for 2027. Management deferred the enrollment update to February; a bigger membership decline than flagged would add to the 2027 trough-year pressure.

What would change the view

A daily close below $81, under the $81.33 close of 5 November 2026 after the split announcement, which would show the rebound has failed; or a cut of the 2027 adjusted EPS outlook below $8.65 per share.

The risks this note tracks, each with what would confirm it:

• Medical cost trends rise again and reverse the improvement in Aetna's medical benefit ratio. Confirmed by: a fourth-quarter 2026 medical benefit ratio above the year-earlier level, or managed-care peers reporting higher cost trends in their fourth-quarter results.
• Rebate guarantees and the 340B drug pricing program pressure 2027 earnings at Caremark more than guided. Confirmed by: management lowering the 2027 adjusted EPS outlook of at least $8.65, or citing larger pharmacy-benefit headwinds at the fourth-quarter report.
• Separation costs and dis-synergies come in above management's estimate of about $500 million a year. Confirmed by: separation filings or management guidance putting recurring standalone costs well above $500 million, or large one-time costs that cut cash flow guidance.
• AM Best's review leads to a downgrade of Aetna insurance subsidiaries. Confirmed by: AM Best concluding its review with a downgrade or a negative outlook on Aetna Life Insurance Company.
• Regulatory action against pharmacy-benefit managers that own retail pharmacies. Confirmed by: new state or federal legislation forcing changes to Caremark's ownership or contracts before the 2028 separation.

What it trades with

CVS Health trades mostly with large managed-care insurers, because Aetna's medical cost ratio drives the swings in earnings. Cost-trend comments from peers move the shares, as do Medicare Advantage enrollment updates; management said on 9 November 2026 that its next enrollment update comes in February. The Caremark benefits manager and the retail pharmacies add exposure to drug-pricing and pharmacy-benefit regulation that pure insurers do not carry.